Home › Funds › HighVista Strategies LLC › CCCC
HighVista Strategies LLC position in CCCC
C4 THERAPEUTICS INC · Health Care
HighVista Strategies LLC reported holding 873,277 shares of CCCC (C4 THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.9M, representing 0.76% of its reported portfolio and ranking #37 among its reported holdings. HighVista Strategies LLC has disclosed CCCC holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How HighVista Strategies LLC's CCCC position evolved
HighVista Strategies LLC first disclosed a stake in CCCC in Q2 2026 at 1,348,136 shares (US$6.3M). Across 2 filings, HighVista Strategies LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 873,277 shares valued at US$2.9M — a reduction of -474,859 shares quarter over quarter.. Notable position changes include a 35% trim in Q3 2026 (shares fell 17% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.35M | $6.30M | New |
| Q3 2026 | 873.28K | $2.91M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CCCC and 13F data
CCCC (C4 THERAPEUTICS INC) is a Health Care company. 49 other funds we track also report a position in CCCC — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$37.4M), Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CCCC
- RA CAPITAL MANAGEMENT, L.P. 8.00M sh · $37.36M · Q2 2026
- Lynx1 Capital Management LP 7.33M sh · $34.22M · Q2 2026
- Bain Capital Life Sciences Investors, LLC 7.17M sh · $33.49M · Q2 2026
- Soleus Capital Management, L.P. 3.38M sh · $15.78M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 3.45M sh · $11.50M · Q3 2026
- Ikarian Capital, LLC 2.43M sh · $11.36M · Q2 2026
- Velan Capital Investment Management LP 570.00K sh · $2.66M · Q2 2026
- Squadron Capital Management LLC 400.00K sh · $1.87M · Q2 2026
- Seven Fleet Capital Management LP 381.17K sh · $1.78M · Q2 2026
More on HighVista Strategies LLC
FAQ
How long has HighVista Strategies LLC held CCCC?
HighVista Strategies LLC has disclosed CCCC holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is HighVista Strategies LLC's current position in CCCC?
As of Q3 2026, HighVista Strategies LLC holds 873.28K shares of CCCC (C4 THERAPEUTICS INC), valued at $2.91M, representing 0.76% of its reported portfolio and ranking #37.
Has HighVista Strategies LLC been buying or selling CCCC?
In the latest 13F filing (Q3 2026), HighVista Strategies LLC reduced its position in CCCC.
Which other funds hold CCCC?
Other major institutional holders of CCCC include RA CAPITAL MANAGEMENT, L.P., Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.